Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00038584 · ClinicalTrials.gov registry record · Phase 1

A Phase IB Study Of Oral SCH 66336 Preoperatively In Patients With Head And Neck Squamous Cell Cancer

A Phase 1 study, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
Phase 1
Development phase
37
Enrollment target

NCT00038584: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.

NCT00038584 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 37 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00038584, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
37 participants
Enrollment target

Study Summary

SCH66336 is a drug that has been designed to block the growth of tumor cells and encourage tumor cell death. This is a randomized study where patients will receive study drug or no drug. Participants in this study are scheduled to have surgery to remove head and neck cancer.

Interventions

  • DRUG SCH66336

Trial Details

FieldValue
Enrollment Target 37 participants
Start Date 1999-06
Est. Completion 2004-11
Phase Phase 1

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

What the Registry Record Tells You About NCT00038584

The ClinicalTrials.gov registry entry for NCT00038584 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which SCH66336 is the first listed.

NCT00038584 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00038584 about?

NCT00038584 is a clinical study titled "A Phase IB Study Of Oral SCH 66336 Preoperatively In Patients With Head And Neck Squamous Cell Cancer". SCH66336 is a drug that has been designed to block the growth of tumor cells and encourage tumor cell death. This is a randomized study where patients will receive study drug or no drug. Participants in this study are scheduled to have surgery to remove head and neck cancer.

What is the current status of trial NCT00038584?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 1999-06. Estimated completion is 2004-11.

What interventions are being tested in trial NCT00038584?

The interventions under investigation include: SCH66336 (DRUG).

Who is sponsoring clinical trial NCT00038584?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.